Endo acquires NuPathe for $105 million

Acquisition gives Endo control of migraine treatment, Zecuity

MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.

Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe's patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.

"The acquisition of NuPathe enhances our branded pharmaceutical portfolio and is well-aligned with our strategy of acquiring late-stage products for commercialization," said Endo president and CEO Rajiv De Silva. "We're excited about the opportunity to launch Zecuity, a treatment that could be an option for millions of migraine patients, including those with migraine-related nausea."


Login or Register to post a comment.